ML6710i
Modulight's cloud-connected ophthalmic laser platform
ML6710i is a medical laser device for ophthalmology. ML6710i is designed for treatments in various ophthalmic indications. The laser is controlled intuitively from iPad app – the wireless connection allows flexibility for the treatment setup. A must-have tool for anyone in the field of ophthalmology. The laser beam is formed into a circular, adjustable and highly uniform spot by Modulight’s laser beam shaper.
Designed for Retina
Every part and feature within ML6710i is designed to fulfill one goal: Enabling safe and efficient ophthalmic treatments for patients and doctors. Read here why Bausch + Lomb chose Modulight as their exclusive laser provider.
The laser itself is packaged in an elegant and durable metallic case. The laser device is accompanied by an iPad, which is used for setting up the treatment and controlling the laser. The user interface has been optimized for easiness of use, while keeping up with the strict requirements of a medical laser.
ML6710i is connected to Modulight cloud, which enables safe storing of treatment logs, while not exposing patient data.
The laser light is formed into a uniform circular spot by Modulight laser beam shaper. The beam shaper can be attached into all common slit lamps.
ML6710i has the standard wavelength of 689 nm but according to customer wishes it can be built to include a different wavelength. When ordering, you may request a wavelength from UV to 2000+ nm – just ask Modulight sales team.
Modulight's cloud connected ophthalmic laser platform ML6710i
Modulight ML6710i Laser
-
Laser main unit
-
iPad with ML6710i App, wirelessly connected to the ML6710i laser and Modulight Cloud
-
Foot switch for enabling laser emission
-
Beam shaping unit
-
Slit lamp
-
Instrument table with height adjustment
Key features
- The default built-in laser is 689 nm, 400 mW output power
- Aiming beam (laser class 2) 635 nm
- Possible to select any other Modulight laser in the wavelength range of 400–2000 nm and power up to 3 W
- Laser beam shaper easily attached to all common slit lamps
- Treatment spot diameter adjustable to up to 14 mm diameter with 600 mW/cm2
- Laser on/pause controlled by a foot switch
- Key switch and interlock for laser safety
Benefits
- ML6710i is a modern ophthalmic laser which is very easy an intuitive to operate.
- Thanks to the Modulight Cloud, all the operating parameters and laser on/off/pause events are safely stored into treatment log.
- Setting the treatment parameters is very easy, thanks to the iPad app.
- Laser on/pause can be controlled by a foot switch.
Technical specifications
| Wavelength | Laser output power | Aiming beam | Treatment spot size | Irradiance |
| 689 nm | 400 mW | 635 nm | up to 14 mm | 600 mW/cm2 |
| class 3B | class 2 |
Applications in ophthalmology
• Retinal PDT • Age-related macular degeneration AMD • Uveal melanoma • Ocular melanoma • Choroidal melanoma • Pathological myopia • Central serous retinopathy CSR • Polypoidal choroidal vasculopathy PCV •
Typical treatment flow for ML6710i
- Power up the laser device and log into the ML6710i application with your personal login credentials
- Configure desired treatment protocol settings. Settings that can be adjusted are displayed on blue.
- Select the preferred contact lens.
- Press start treatment and proceed to positioning contact lens.
- Start laser with foot switch.
- Treatment is completed after configured time and log is sent to Modulight cloud.
Laser connection status & my settings view
Modulight Cloud Analytics and Services
Modulight Cloud
- User authentication to prevent unauthorized use
- Personal user account and settings
- Each treatment is recorded into the treatment history
- Periodic summary report
- Access to online guidebook and up-to-date training materials 24/7
- Customer support to minimize the downtime (e.g. scheduling preventive maintenance)
- Support chat integrated into the App for reaching tech support easily
- Real-time device diagnostics for remote troubleshooting
- Over-the-air software updates à faster access to new features
ML6710i case examples
Novel ophthalmic laser system paired with focal electroretinography for subthreshold laser therapy of DME
In the field of ophthalmic treatments, subthreshold laser therapy (SLT) has shown promise in addressing retinal diseases like diabetic macular edema (DME) and age-related macular degeneration (AMD). However, the precise control of therapeutic temperatures is challenging due to variations in individual eye characteristics. Modulight and Maculaser have addressed this issue with their innovative ML6710i device. This device utilizes a combination of laser beams to achieve precise thermal dosimetry-controlled retinal laser treatments. By monitoring focal electroretinography (fERG) from the target tissue, temperature-dependent changes are analyzed, ensuring accurate therapeutic temperatures for each patient. The device features an iOS-based graphical user interface (GUI), live fundus view, and data storage in the Modulight Cloud.
Novel ophthalmic PDT laser platform to target oncology and various other retinal indications
Laser systems, in ophthalmic applications, are utilized in the treatment of various ophthalmic diseases such as in ocular oncology and age-related macular degeneration through photochemical mechanism of photodynamic therapy. In addition, these lasers can be used to activate drug delivery systems in the retina to provide targeted drug therapy. PDT is a form of a combination treatment which utilizes light energy to activate a photoactive pharmaceutical (photosensitizer) to create a photodynamic reaction. Current photodynamic therapy devices out on the market are around 20 years old and the companies that manufacture the devices, do not provide yearly maintenance services for the devices.
Vision-sparing targeted phototherapy for uveal melanoma
AU-011 is cytotoxic only when photoactivated with ML6710i ophthalmic laser, sparing surrounding key eye structures from damages. Its novel dual mechanisms of action act directly on the tumor via membrane disruption of tumor cells and indirectly by activating T cells through release of neoantigens from the damaged tumor cells. The activation of antitumor immunity has the potential to possibly result in the long-term survival of the treated patients. This phototherapy is well-tolerated, convenient, and a cost-effective treatment that can be given in an outpatient setting.